Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Andrea Zimmer, Michael Coslovsky, Ivo Abraham & Bernhard F Décard. (2017) Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study. Patient Preference and Adherence 11, pages 1815-1830.
Read now
Read now
María Dolores Edo Solsona, Emilio Monte Boquet, Bonaventura Casanova Estruch & José Luis Poveda Andrés. (2017) Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis. Patient Preference and Adherence 11, pages 415-421.
Read now
Read now
Jack Burks, Thomas S Marshall & Xiaolan Ye. (2017) Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEconomics and Outcomes Research 9, pages 251-260.
Read now
Read now
Nina Parikh Thomas, Suellen Curkendall, Amanda M. Farr, Elaine Yu & Dana Hurley. (2016) The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. Journal of Medical Economics 19:5, pages 497-505.
Read now
Read now
Luis Lizán, Marta Comellas, Silvia Paz, José Luis Poveda, Dennis M Meletiche & Carlos Polanco. (2014) Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Preference and Adherence 8, pages 1653-1664.
Read now
Read now
Niklas Bergvall, Allison A. Petrilla, Swapna U. Karkare, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Charles Makin, Catherine Balderston McGuiness & Jonathan R. Korn. (2014) Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Journal of Medical Economics 17:10, pages 696-707.
Read now
Read now
Jonathan H. Watanabe, Mark Bounthavong & Timothy Chen. (2013) Revisiting the medication possession ratio threshold for adherence in lipid management. Current Medical Research and Opinion 29:3, pages 175-180.
Read now
Read now
Articles from other publishers (23)
Laura Maria Beatrice Belotti, Mirko Di Martino, Corrado Zenesini, Luca Vignatelli, Elisa Baldin, Flavia Baccari, Ben Ridley & Francesco Nonino. (2023) Impact of adherence to disease-modifying drugs in multiple sclerosis: A study on Italian real-world data. Multiple Sclerosis and Related Disorders 80, pages 105094.
Crossref
Crossref
N. Giedraitiene, V. Taluntiene & G. Kaubrys. (2022) Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. Scientific Reports 12:1.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. JohnstonJessina C. McGregorDennis N. Bourdette. (2022) Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. International Journal of MS Care 24:2, pages 90-97.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. JohnstonJessina C. McGregor & Dennis N. Bourdette. (2022) Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program. Neurology Clinical Practice 12:1, pages 36-42.
Crossref
Crossref
Joshua MardanMohammad Akhtar HussainMichelle AllanLisa B Grech. (2021) Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1273-1295.
Crossref
Crossref
Daniel M. Hartung. (2021) Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Natalie J EngmannDanny SheinsonKomal BawaCarmen D NgGabriel Pardo. (2021) Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. Journal of Managed Care & Specialty Pharmacy 27:5, pages 639-649.
Crossref
Crossref
Maria Cecilia Vieira, Yunfeng Li, Xiangyi Meng, Huanxue Zhou, Olivia Wenxian Piao, Christen Kutz & Devon Conway. (2021) Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis–Related Relapses. International Journal of MS Care 23:2, pages 73-78.
Crossref
Crossref
Daniel M. Hartung. (2021) Health economics of disease-modifying therapy for multiple sclerosis in the United States. Therapeutic Advances in Neurological Disorders 14, pages 175628642098703.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. Johnston, Jessina C. McGregor & Dennis N. Bourdette. (2020) The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. Multiple Sclerosis and Related Disorders 46, pages 102554.
Crossref
Crossref
Motoyasu Miyazaki, Masanobu Uchiyama, Yoshihiko Nakamura, Koichi Matsuo, Chika Ono, Miwa Goto, Ayako Unoki, Akio Nakashima & Osamu Imakyure. (2020) Association of Self-Reported Medication Adherence with Potentially Inappropriate Medications in Elderly Patients: A Cross-Sectional Pilot Study. International Journal of Environmental Research and Public Health 17:16, pages 5940.
Crossref
Crossref
Pierre Duquette, Michael Yeung, Soukaïna Mouallif, Hamid Reza Nakhaipour, Paola Haddad & Robyn Schecter. (2019) A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies. PLOS ONE 14:1, pages e0210417.
Crossref
Crossref
Michel Burnier. (2019) Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence. Frontiers in Pharmacology 9.
Crossref
Crossref
Yu. A. Pichkaleva, T. V. Baidina, T. N. Trushnikova, M. A. Danilova & T. P. Kalashnikova. (2019) The effect of psychological gender on adherence to immunomodulatory therapy in patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:10, pages 96.
Crossref
Crossref
Pascal C. Baumgartner, R. Brian Haynes, Kurt E. Hersberger & Isabelle Arnet. (2018) A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes. Frontiers in Pharmacology 9.
Crossref
Crossref
Shail M Govani, Mohamed Noureldin, Peter D R Higgins, Michele Heisler, Sameer D Saini, Ryan W Stidham, Jennifer F Waljee & Akbar K Waljee. (2018) Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. American Journal of Gastroenterology 113:2, pages 276-282.
Crossref
Crossref
Brittany Gerber, Tara Cowling, Guanmin Chen, Michael Yeung, Pierre Duquette & Paola Haddad. (2017) The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. Multiple Sclerosis and Related Disorders 18, pages 218-224.
Crossref
Crossref
Andy Pulvermacher & Carl Nelson. (2016) Benefits of developing a collaborative, outcomes-based specialty pharmacy program. American Journal of Health-System Pharmacy 73:11, pages 839-843.
Crossref
Crossref
Wei-Hsuan Lo-Ciganic, Julie M. Donohue, Joshua M. Thorpe, Subashan Perera, Carolyn T. Thorpe, Zachary A. Marcum & Walid F. Gellad. (2015) Using Machine Learning to Examine Medication Adherence Thresholds and Risk of Hospitalization. Medical Care 53:8, pages 720-728.
Crossref
Crossref
D J Hyman & V Pavlik. (2014) Medication adherence and resistant hypertension. Journal of Human Hypertension 29:4, pages 213-218.
Crossref
Crossref
B.A. Cohen, P.K. Coyle, T. Leist, M.A. Oleen-Burkey, M. Schwartz & H. Zwibel. (2015) Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse. Multiple Sclerosis and Related Disorders 4:1, pages 75-82.
Crossref
Crossref
Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, MerriKay Oleen-Burkey, Marc Schwartz, Mark J Tullman & Howard Zwibel. (2014) Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurology 14:1.
Crossref
Crossref
Claudia Soares & Gulnar Azevedo Silva. (2013) Uso de registros de assistência farmacêutica do Sistema de Informações Ambulatorial para avaliação longitudinal de utilização e adesão a medicamentos. Cadernos Saúde Coletiva 21:3, pages 245-252.
Crossref
Crossref